Clicky

Syndax Pharmaceuticals, Inc.(SNDX)

Description: Syndax Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics in oncology. The company's lead product candidate is entinostat, an epigenetic therapy for treatment-resistant cancers, such as breast cancer and lung cancer, as well as other indications comprising solid tumors and hematological malignancies. Its Entinostat is an oral histone deacetylase inhibitor that targets cancer cell growth and resistance pathways that limit the effectiveness and durability of cancer therapies. The company has a collaborative research and development agreement with the National Cancer Institute; and Genentech. Syndax Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Waltham, Massachusetts.


Keywords: Medicine Cancer Clinical Medicine Solid Tumors Breast Cancer Lung Cancer Antineoplastic Drugs Treatment Of Breast Cancer Cancer Therapies Hematological Malignancies Cancer Cell National Cancer Institute Pyridines Benzamides Carbamates Late Stage Biopharmaceutical Entinostat Histone Deacetylase Inhibitor Treatment Resistant Cancers

Home Page: www.syndax.com

SNDX Technical Analysis

35 Gatehouse Drive
Waltham, MA 02451
United States
Phone: 781 419 1400


Officers

Name Title
Mr. Michael A. Metzger M.B.A. CEO & Director
Dr. Briggs W. Morrison M.D. Pres, Head of R&D and Director
Dr. Anjali Ganguli Ph.D. Chief Bus. Officer
Dr. Peter Ordentlich B.Sc., Ph.D. Co-Founder & Chief Scientific Officer
Dr. Richard A. Heyman Ph.D. Co-Founder
Dr. Ronald M. Evans Ph.D. Co-Founder, Advisor and Chair of Scientific Advisory Board
Dr. Michael Downes Ph.D. Co-Founder
Mr. Keith Alan Goldan CPA Chief Financial Officer
Mr. Alexander Nolte VP & Chief Accounting Officer
Sharon Klahre VP of Investor Relations & Communications

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 122
Price-to-Book MRQ: 4.8719
Price-to-Sales TTM: 12.6667
IPO Date: 2016-03-03
Fiscal Year End: December
Full Time Employees: 59
Back to stocks